Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494975 | 0.66 | GRM1 (0.41) | RAB9ANPC1GRM1 | |
| SCHEMBL3671286 | 0.63 | HPGD (0.65) | LMNARAB9ANPC1GRM1HPGD | |
| SCHEMBL30355896 | 0.63 | HPGD (0.65) | LMNARAB9ANPC1GRM1HPGD | |
| SCHEMBL1515418 | 0.61 | RAB9A (0.60) | LMNARAB9ANPC1GRM1HPGD | |
| SCHEMBL27488421 | 0.61 | RAB9A (0.63) | RAB9ANPC1HPGDGAA | |
| SCHEMBL10352433 | 0.61 | RAB9A (0.66) | POLBLMNARAB9ANPC1HPGD | |
| SCHEMBL1554009 | 0.60 | RAB9A (0.53) | POLBLMNARAB9ANPC1HPGD | |
| SCHEMBL1554007 | 0.60 | RAB9A (0.53) | POLBLMNARAB9ANPC1HPGD | |
| SCHEMBL5139794 | 0.60 | RAB9A (0.65) | LMNARAB9ANPC1HPGD | |
| SCHEMBL30359426 | 0.60 | NPC1 (0.53) | LMNARAB9ANPC1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861529-B2 | Cycloalkylpyrrole-3-carboxylic acid amide derivatives and heterocycloalkylpyrrole-3-carboxylic acid amide derivatives that bind with high affinity to the benzodiazepine site of GABA-A (gamma-aminobutyric acid) receptors | PFIZER INC (US) | 2005-03-01 | — | — | US | claimed |
| US-20030069416-A1 | Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives | PFIZER INC. | 2003-04-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069416-A1 | Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives | GABARAP, GABRA3, GABRA2 | POLB 4186/4885LMNA 4325/4885RAB9A 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.